HDL Cholesterol: Physiology, Pathophysiology, and Management

Current Problems in Cardiology

Volumn 32, Issue 5, 2007, Pages 268-314

  Link, Jeffrey J ^a   Rohatgi, Anand ^a   de Lemos, James A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTYRAMINE; ENDOCANNABINOID; ESTROGEN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVINOLIN; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; VACCINE;

ALCOHOL CONSUMPTION; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET RESTRICTION; DRUG TARGETING; EXERCISE; FLUSHING; FUNCTIONAL ASSESSMENT; HEREDITY; HOMOCYSTINURIA; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KINETICS; LIPID METABOLISM; LIVER TOXICITY; MEDICAL RESEARCH; MONOTHERAPY; MORTALITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; WEIGHT CONTROL;

ANIMALS; CHOLESTEROL, HDL; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; LIFE STYLE; LIPID PEROXIDATION; OXIDATIVE STRESS; PRACTICE GUIDELINES; RISK FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 34247619743     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2007.01.004     Document Type: Article

References (145)

1. Gordon T., Castelli W.P., Hjortland M.C., et al. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 62 (1977) 707-714
2. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
3. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 354 (2004) 937-952
4. Johnson C.L., Rifkind B.M., Sempos C.T., et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination surveys. JAMA 269 (1993) 3002-3008
5. Rubins H.B., Robins S.J., Collins D., et al., Department of Veterans Affairs HDL Intervention Trial Study Group. Distribution of lipids in 8500 men with coronary artery disease. Am J Cardiol 75 (1995) 1196-1201
6. Sacks F.M., Tonkin A.M., Craven T., et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105 12 (2002) 1424-1428
7. Goulinet S., and Chapman M.J. Plasma LDL and HDL subspecies are heterogeneous in particle content of tocopherols and oxygenated and hydrocarbon caretenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 17 (1997) 786-796
8. Navab M., Ananthramaiah G.M., Reddy S.T., et al. The oxidation hypothesis of atherogenesis; the role of oxidized phospholipids and HDL. J Lipid Res 45 (2004) 993-1007
9. Gordon D.J., and Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
10. Yancey P.G., Bortnick A.E., Kellner-Weibel G., et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Vasc Biol 23 (2003) 712-719
11. Wang N., Silver D.L., Thiele C., et al. ATP-binding cassette transporters G1 and G4 mediate cellular efflux to high densiy lipoproteins. Proc Natl Acad Sci USA 101 (2004) 9774-9779
12. Barter P.J., and Kastelein J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 47 (2006) 492-499
13. Williams D.L., Connelly M.A., Temel R.E., et al. Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipid 10 (1999) 329-339
14. Schwartz C.C., VandenBroek J.M., Cooper P.S., et al. Lipoprotein cholesteryl ester production, transfer and output in humans. J Lipid Res 45 (2004) 1594-1607
15. Puchois P., Kaul S., Nilsson J., et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 68 (1987) 35-40
16. Huang Y., von Eckardstein S., Wu S., et al. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 15 (1995) 1412-1418
17. Fan Y.M., Salonen J.T., Koivu T.A., et al. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 84 (1991) 129-139
18. Asztalos B.F., Collins D., Cupples L.A., et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol 25 (2005) 2185-2191
19. Yla-Herttuala S. Oxidized LDL and atherogenesis. Ann NY Acad Sci 874 (1999) 134-137
20. Parthasarathy S., Barnett J., Fong L.G., et al. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. PG-275-83. Biochim Biophys Acta 1044 (1990) 275-283
21. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 (2001) 481-488
22. Galle J., Ochslen M., Schollmeyer P., et al. Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein. Hypertension 23 (1994) 556-564
23. Libby P., Ridker P.M., Maseri A., et al. Inflammation and atherosclerosis. Circulation (2002) 1135-1143
24. Dimayuga P., Zhu J., Oguchi S., et al. Reconstituted HDL containing apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 264 (1999) 465-468
25. Cockerill G.W., Huehns T.Y., Weerasinghe A., et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1 induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103 (2001) 108-112
26. Spieker L.E., Sudano I., Hurlimann D., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
27. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high-density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276;34480-5.
28. Ansell B.J., Watson K.E., Fogelman A.M., et al. High-density lipoprotein function: recent advances. JACC 46 (2005) 1792-1798
29. Yuhanna I.S., Zhu Y., Cox B.E., et al. High density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase. Nat Med 7 (2001) 853-857
30. Li X.A., Titlow W.B., Jackson B.A., et al. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide syntase in a ceramide-dependent manner. J Biol Chem 277 (2002) 11058-11063
31. Nofer J.R., Levkau B., Wolinska I., et al. Suppression of endothelial cell apotosis by high-density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Clin Invest 113 (2004) 569-581
32. Fleisher L.N., Tall A.R., Witte L.D., et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 257 (1982) 6653-6655
33. Horio T., Kohno M., Yasunari K., et al. Stimulation of endothelin-1 release by low density and very low density lipoproteins in cultured human endothelial cells. Atherosclerosis 101 (1993) 185-190
34. Kuhn F.E., Mohler E.R., Satler L.F., et al. Effects of high-density lipoprotein on acetylcholine-induced vasoreactivity. Am J Cardiol 68 15 (1991) 1425-1430
35. Saku K., Ahmed M., Glass-Greewal P., et al. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 39 1 (1985) 1-8
36. Nofer J.R., Walter M., Kehrel B., et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 18 (1998) 861-869
37. Curtiss L.K., and Plow E.F. Interaction of plasma lipoproteins with human platelets. Blood 64 (1984) 365-374
38. Griffin J.H., Kojima K., Banka C.L., et al. High density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103 (1999) 219-227
39. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. (Adult Treatment Panel III). Final Report. Circulation 106 (2002) 3143-3421
40. Assmann G, von Eckardstein A, Funke H, et al. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 87;III28-34.
41. Patel S.B., Honda A., Salen G., et al. Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. J Clin Invest 102 5 (1998) 1041-1044
42. Hobbs H.H., Russell D.W., Brown M.S., et al. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24 (1990) 133-170
43. Knoblauch H., Bauerfeind A., Toilat M.R., et al. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet 13 (2004) 993-1104
44. Hansel B., Giral P., Nobecourt E., et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89 (2004) 4963-4971
45. Lamon-Fava S., Wilson P.W.F., Schaefer E.J., et al. Impact of BMI on coronary heart disease risk factors in men and women; the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 16 (1996) 1509-1515
46. Datillo A.M., and Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56 (1992) 320-328
47. Ginsberg H.N., Kris-Etherton P., Dennis B., et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA study, protocol 1. Arterioscler Thromb Vasc Biol 18 (1998) 441-449
48. Ginsberg H. Nonpharmacologic management of low levels of high-density lipoprotein cholesterol. Am J Cardiol 86 s (2000) 41L-45L
49. Lichtenstein A.H., Ausman L.M., Jalbert S.M., et al. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 340 (1999) 1933-1940
50. Harper C.R., and Jacobson T.A. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 161 18 (2001) 2185-2192
51. Nestel P.J., Connor W.E., Reardon M.F., et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 74 1 (1984) 82-89
52. Harris W.S. N-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 31 (1996) 243-252
53. Frenais R., Ouguerram K., Maugeais C., et al. Effect of dietary -3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis 157 (2001) 131-135
54. Thompson P.D. What do muscles have to do with lipoproteins?. Circulation 81 (1990) 1428-1430
55. Zmuda J.M., Yurgalevitch S.M., Flynn M.M., et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis 137 (1998) 215-221
56. Hardman A.E., et al. Role of exercise and weight loss in maximizing LDL cholesterol reduction. Eur Heart J Suppl 1 suppl S (1999) S123-S131
57. An P., and Borecki I.B. Evidence of major genes for plasma HDL, LDL cholesterol and triglyceride levels at baseline and in response to 20 weeks of endurance training: the HERITAGE Family Study. Int J Sports Med 26 (2005) 414-419
58. Lakier J.B. Smoking and cardiovascular disease. Am J Med 93 (1992) 8S-12S
59. Garrison R.J., Kannel W.B., Feinleib M., et al. Cigarette smoking and HDL cholesterol: the Framingham Offspring Study. Atherosclerosis 30 (1978) 17-25
60. Rimm E.B., Williams P., Fosher K., et al. Moderate alcohol intake and lower risk of coronary heart disease: a meta-analysis of effects on lipids and haemostatic factors. BMJ 319 (1999) 1523-1528
61. Lin R.C., and Lumeng L. Effect of chronic ethanol feeding on high density lipoprotein subfractions in rats. Alcohol Clin Exp Res 15 (1991) 207-211
62. Kashyap M.L., Tavintharan S., and Kamanna V.S. Optimal therapy of low levels of high density lipoprotein-cholesterol. Am J Cardiovasc Drugs 3 1 (2003) 53-65
63. Jin F.Y., Kamanna V.S., Kashyap M.L., et al. Niacin accelerates intracellular ApoB degredation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 19 (1999) 1051-1059
64. Jin F.Y., Kamanna V.S., Kashyap M.L., et al. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Basc Biol 17 (1997) 2020-2028
65. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
66. Brown B.G., Zhao X.-Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
67. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
68. Whitney E.J., Krasuski R.A., Personius B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
69. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. JACC 8 6 (1986) 1245-1255
70. Morgan J.M., Capuzzi D.M., Baksh R.I., et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91 12 (2003) 1432-1436
71. Probstfield J.L., and Hunninghake D.B. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med 154 (1994) 1557
72. Illingworth D.R., Stein E.A., Mitchel Y.B., et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 154 (1994) 1586-1595
73. Staels B., Dallongeville J., Schoonjans K., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
74. Chawla A., and Boisvert W.A. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58
75. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
76. Guyton J.R., Blazing M.A., Hagar J., et al. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia. Arch Intern Med 160 (2000) 1177-1184
77. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
78. McKenney J.M., McCormick L.S., Weiss S., et al. Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol 83 9B (1999) 30F-35F
79. Schaefer J.R., Schweer H., Ikewaki K., et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144 (1999) 177-184
80. Chapman M.J. Are the effects of statins on HDL-cholesterol clinically relevant?. Eur Heart J 6 suppl C (2004) C58-C63
81. Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001) 577-581
82. Jones P., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvistatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92 (2003) 152-160
83. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102 (2000) 1893-1900
84. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
85. Cannon C.P., Braunwald E., McCabe C.H., et al., Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
86. Gotto A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
87. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
88. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345 (1995) 1274-1275
89. http://www.clinicaltrials.gov/ct/show/NCT00120289?order=1
90. http://www.clinicaltrials.gov/ct/show/NCT00000620?order=4
91. Zetia (ezetimibe) package insert. Kenilworth, NJ: Schering Corporation, 2002.
92. Altmann S.W., Davis Jr. H.R., Zhu L.J., et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303 (2004) 1201-1204
93. Sudhop T., and von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 62 (2002) 2333-2347
94. Ballantyne C.M., Houri J., Notabartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2415
95. Lehmann J.M., Lenhard J.M., Oliver B.B., et al. An antidiabetic thiazoladinedione is a high affinity ligand for peroxisome proliferators-activated receptor-gamma (PPAR-gamma). J Biol Chem 270 (1995) 12953-12956
96. Sakamoto J., Kimura H., Moriyama S., et al. Activation of human peroxisome proliferators-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278 (2000) 704-711
97. Nagashima K., Lopez C., Donovan D., et al. Effects of the PPAR-γ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115 (2005) 1323-1332
98. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351;11:1106-18.
99. Szapary P.O., Bloedon L.A.T., Samaha F.F., et al. Effects of pioglitazone on lipoproteins, inflammatory markers and adipokines in nondiabetic patients with metabolic syndrome. Atherioscler Thromb Vasc Biol 26 (2006) 182-188
100. Dormandy J.A., Charbonnel B., Eckland D.L.A., et al. Secondary prevention of macrovascular events in patients with type two diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial I macrovascular Events): a randomized control trial. Lancet 366 (2005) 1279-1289
101. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
102. Cabrero A., Cubero M., Llaver G., et al. Differential effects of peroxisome proliferator-activated receptor activators of the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52 (2003) 652-657
103. Winkler K., Konrad T., Fullert S., et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26 (2003) 2588-2594
104. Gerstein H.C. Rationale, design and recruitment of a large, simple, international trial of diabetes prevention: the DREAM trial. Diabetologica 47 (2004) 1519-1527
105. Saad M.F., Greco S., Osei K., et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects. Diabetes Care 27 6 (2004) 1324-1329
106. Nissen S.E., Wolski K., Topol E.J., et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 20 (2005) 2581-2586
107. Miller K.W., and Lane M.D. Estradiol-induced alteration of very-low-density lipoprotein assembly. Possible competition among apoproteins for incorporation into nascent very-low-density lipoprotein. J Boil Chem 259 (1984) 15277-15286
108. Walsh B.W., and Schiff I. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325 (1991) 1196-1204
109. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the ris of coronary heart disease. N Engl J Med 349 (2003) 523-534
110. Grey A.B., Stapleton J.P., Evans M.C., et al. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab (1995) 3191-3195
111. Barrett-Connor E., Mosca L., Collins P., et al. Effects of Raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2006) 125-137
112. Van Lenten B.J., Wagner A.C., Nayak D.P., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96 (1995) 2758-2767
113. Despres J.-P., Golay A., Sjostrom L., et al. Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
114. Van Gaal L.F., Rissanen A., Scheen A.J., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
115. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
116. Franceschini G., and Magani D. Relationship of the phenotypic expression of apo-A-I Milano apoprotein with plasma lipid and lipoprotein patterns. Circulation 97 (1998) 780-785
117. Gualandri V., Franceschini G., Sirtori C.R., et al. Identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 37 (1985) 1083-1097
118. Sirtori C.R., Calabresi L., Franceschini G., et al. Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda Study. Circulation 103 (2001) 1949-1954
119. Franceschini G., Calabresi L., Chiesa G., et al. Increased cholesterol efflux potential of sera from apo-A-I Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 19 (1999) 1257-1262
120. Shah P.K., Yano J., Reyes O., et al. High dose recombinant apo-A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein-e deficient mice. Circulation 103 (2001) 3047-3050
121. Nissen S., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 290 (2003) 2292-2300
122. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Human apolipoprotein A-I and A-I mimetic peptides:potential for atherosclerosis reversal. Curr Opin Lipidol 15 (2004) 645-649
123. Brown M.L., Inazu A., Hesler C.B., et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342 (1989) 448-451
124. Ordovas J.M. Association of cholesteryl ester transfer protein-TaqB1 polymorphism with variations in lipoprotein subclasses and coronary heart disease ris:the Framingham study. Arteriosclerosis Vasc Biol 20 (2000) 1323-1329
125. Okamato H., and Yonemori F. A cholesteryl ester transfer protein attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
126. Morehouse LA. The CETP-inhibitor Torctrapib raises HDL and prevents aortic atherosclerosis in rabbits. Presented at XV International Symposium on Drugs Affecting Lipid Metabolism, October 24 to 27, 2004, Venice, Italy.
127. Rittershaus C.W., Miller D.P., Thomas L.J., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model or atherosclerosis. Ateriosclerosis Thromb Vasc Biol 20 (2000) 2106-2112
128. Huang Z., Inazu A., Nohara A., et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 103 (2002) 587-594
129. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
130. Klerkx A.H., de Grooth G.J., Zwinderman A.H., et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 34 (2004) 21-28
131. Boekholdt S.M., Kuivenhoven J.A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women:the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk population study. Circulation 110 (2004) 1418-1423
132. De Grooth G.J., Smilde T.J., Van Wissen S., et al. The relationship between cholesteryl ester transfer protein levels and risk profile in patients with familial hypercholesterolemia. Atherosclerosis 173 (2004) 261-267
133. Davidson M.H., Maki K., Umporowicz D., et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 169 (2003) 113-120
134. De Grooth GJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105:2159-65.
135. Kuivenhoven J.A., and Stalenhoef A.F. Inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95 (2005) 1085-1088
136. Bisoendial R.J., Hovingh G.K., Harchaoui K., et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 25 (2005) e133-e134
137. Clark R.W., Sutfin T.A., Ruggeri R.B., et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497
138. Brousseau M.E., Diffenderfer M.R., Millar J.S., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
139. Clark R.W., Ruggieri R.B., Cunningham D., et al. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 47 (2006) 537-552
140. Davison M. Efficacy and safety of a novel CETP inhibitor torcetrapib administered with and without atorvastatin in subjects with a low level of HDL-C. Am Coll Cardiol Scientific Session 2005 March 6-9 2005, Orlando, FL.
141. Brousseau M.E., Diffenderfer M.R., Millar J.S., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25 (2005) 1057-1064
142. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. (Adult Treatment Panel III). Final Report. Circulation 106 (2002) 3142-3421
143. American Diabetes Association Position Statement. Dyslipidemia management in adults with diabetes. Diabetes Care 27 suppl 1 (2004) S68-S71
144. Mosca L., Appel L.J., Benjamin E.J., et al., American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 5 (2004) 672-693
145. Harper C.R., and Jacobson T.A. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 159 10 (1999) 1049-1057